Analysts at Summer Street Research upped their price target on shares of Ariad Pharmaceutical (NASDAQ: ARIA) from $16.00 to $21.00 in a research report issued to clients and investors on Monday. The firm currently has a “buy” rating on the stock.
ARIA has been the subject of a number of other recent research reports. Analysts at Jefferies Group (NYSE: JEF) raised their price target on shares of Ariad Pharmaceutical to $18.00 in a research note to investors on Thursday, May 10th. Separately, analysts at UBS AG (NYSE: UBS) initiated coverage on shares of Ariad Pharmaceutical in a research note to investors on Thursday, April 12nd. They set a “buy” rating and a $20.00 price target on the stock. Finally, analysts at Stifel Nicolaus cut their price target on shares of Ariad Pharmaceutical to $18.00 in a research note to investors on Wednesday, March 21st.
Ariad Pharmaceutical opened at 17.01 on Monday. Ariad Pharmaceutical has a 52-week low of $7.55 and a 52-week high of $17.28. The company’s market cap is $2.703 billion.
Ariad Pharmaceutical last posted its quarterly earnings results on Wednesday, May 9th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by $0.12. The company’s revenue for the quarter was up 33.3% on a year-over-year basis. Analysts expect that Ariad Pharmaceutical will post $-0.31 EPS next quarter.
ARIAD Pharmaceuticals, Inc. (ARIAD) is a biopharmaceutical company focused on the discovery and development of drugs to provide therapeutic intervention in treating human diseases at the cellular level.